We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective

MedXY Editorial Team•Dec 11, 2025•Neurology
Disease-Modifying Therapymultiple sclerosisPregnancyRelapse Risk

Highlight

– In a national multicenter cohort of 6,341 pregnancies in women with relapsing‑onset MS, DMT management during pregnancy increased relapse rates during gestation and postpartum.

– The highest excess relapse risk was seen after prolonged natalizumab interruption and with fingolimod exposure before pregnancy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Understanding HPA-1a Alloimmunisation in Pregnancy: Insights from a Multi-Ethnic Prospective StudyThis study reveals the population prevalence and incident risk of HPA-1a alloimmunisation in pregnancy across diverse ethnic groups, highlighting its rarity and establishing a framework for risk assessment in foetal-neonatal alloimmune throSep 17, 2026Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal AdenocarcinomaThis analysis of localized appendiceal adenocarcinoma reveals low relapse rates post-resection, identifies key histopathologic and molecular relapse predictors, and finds no significant benefit from adjuvant chemotherapy, challenging convenSep 15, 2026Psychostimulant Continuation and Postpartum Mental Health in Pregnant People With Attention-Deficit/Hyperactivity Disorder: A Clinical Evidence ReviewThis review synthesizes current evidence on the impact of continuing psychostimulant treatment during pregnancy on postpartum mental health outcomes among people with ADHD, highlighting key findings and clinical implications from recent larSep 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Antiseizure Medication Use During Pregnancy: Implications for Fetal Growth from the EURAP Registry
A comprehensive cohort study from the EURAP registry reveals that antiseizure medication, especially polytherapy and certain monotherapies, increases the risk of poor fetal growth, underscoring the need for optimized treatment strategies du
Sep 5, 2026
Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying TherapiesThe HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad thSep 3, 2026
Cascade Genetic Screening in Hereditary Transthyretin Amyloidosis: Unlocking Earlier Diagnosis and Improved OutcomesCascade genetic screening in hereditary transthyretin amyloidosis (ATTRv) enables earlier diagnosis and intervention, improving survival and highlighting the need for variant-specific surveillance strategies.Aug 26, 2026